ProKidney Corp. Class A
(NASDAQ: PROK)
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
3.290
+0.030
(+0.92%)
Jarak
3.160 - 3.500
(10.76%)
Buka
3.385
Tutup Terdahulu
3.260
Harga Beli
10.640
Beli Purata
10
Jual Beli
10.730
Purata Jual
8
Purata
2,775,401
Nilai
-
Catatan
Lihat Semua Acara
Tiada Catatan Tersedia
Please login to view stock data and analysis